Comparing three classes of type 2 diabetes drugs, researchers found one class, which includes Onglyza and Januvia, did not reduce death risk.
Source: Class of type 2 diabetes drugs doesn’t cut death risk compared to placebo
Comparing three classes of type 2 diabetes drugs, researchers found one class, which includes Onglyza and Januvia, did not reduce death risk.
Source: Class of type 2 diabetes drugs doesn’t cut death risk compared to placebo